These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Role of CD2-associated protein and nephrin expression in multilocular cystic renal cell carcinoma]. Gong K; Zhao ZX; Lü TJ; Jin J Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(8):543-7. PubMed ID: 19567077 [TBL] [Abstract][Full Text] [Related]
25. [Multilocular cystic renal cell carcinoma: report of a case]. Kim CJ; Pak K; Tomoyoshi T; Nakajima Y Hinyokika Kiyo; 1991 Feb; 37(2):163-7. PubMed ID: 2048496 [TBL] [Abstract][Full Text] [Related]
26. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma. Alsidawi S; Kasi PM Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387 [TBL] [Abstract][Full Text] [Related]
27. Multilocular cystic renal cell carcinoma: a clinicopathological, immuno- and lectin histochemical study of nine cases. Imura J; Ichikawa K; Takeda J; Tomita S; Yamamoto H; Nakazono M; Takimoto T; Ueda Y; Fujimori T APMIS; 2004 Mar; 112(3):183-91. PubMed ID: 15153160 [TBL] [Abstract][Full Text] [Related]
28. CA9 as a molecular marker for differential diagnosis of cystic renal tumors. Li G; Bilal I; Gentil-Perret A; Feng G; Zhao A; Peoc'h M; Genin C; Tostain J; Gigante M Urol Oncol; 2012; 30(4):463-8. PubMed ID: 20822935 [TBL] [Abstract][Full Text] [Related]
29. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076 [TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695 [TBL] [Abstract][Full Text] [Related]
31. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations? Parilla M; Kadri S; Patil SA; Ritterhouse L; Segal J; Henriksen KJ; Antic T Am J Surg Pathol; 2018 Jul; 42(7):911-917. PubMed ID: 29668487 [TBL] [Abstract][Full Text] [Related]
32. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients. Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718 [TBL] [Abstract][Full Text] [Related]
33. Multilocular cystic renal cell carcinoma: an experience of clinical management for 31 cases. Gong K; Zhang N; He Z; Zhou L; Lin G; Na Y J Cancer Res Clin Oncol; 2008 Apr; 134(4):433-7. PubMed ID: 17846788 [TBL] [Abstract][Full Text] [Related]